191 related articles for article (PubMed ID: 25602964)
1. Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data.
Hall PS; Hamilton P; Hulme CT; Meads DM; Jones H; Newsham A; Marti J; Smith AF; Mason H; Velikova G; Ashley L; Wright P
Br J Cancer; 2015 Mar; 112(5):948-56. PubMed ID: 25602964
[TBL] [Abstract][Full Text] [Related]
2. The economic burden of cancer in the UK: a study of survivors treated with curative intent.
Marti J; Hall PS; Hamilton P; Hulme CT; Jones H; Velikova G; Ashley L; Wright P
Psychooncology; 2016 Jan; 25(1):77-83. PubMed ID: 26087260
[TBL] [Abstract][Full Text] [Related]
3. The association of financial difficulties and out-of-pocket payments with health-related quality of life among breast, prostate and colorectal cancer patients.
Koskinen JP; Färkkilä N; Sintonen H; Saarto T; Taari K; Roine RP
Acta Oncol; 2019 Jul; 58(7):1062-1068. PubMed ID: 30943813
[No Abstract] [Full Text] [Related]
4. Evaluation of trends in the cost of initial cancer treatment.
Warren JL; Yabroff KR; Meekins A; Topor M; Lamont EB; Brown ML
J Natl Cancer Inst; 2008 Jun; 100(12):888-97. PubMed ID: 18544740
[TBL] [Abstract][Full Text] [Related]
5. New analysis reexamines the value of cancer care in the United States compared to Western Europe.
Soneji S; Yang J
Health Aff (Millwood); 2015 Mar; 34(3):390-7. PubMed ID: 25732488
[TBL] [Abstract][Full Text] [Related]
6. Economic disparities in treatment costs among ambulatory Medicaid cancer patients.
Mullins CD; Snyder SE; Wang J; Cooke JL; Baquet C
J Natl Med Assoc; 2004 Dec; 96(12):1565-74. PubMed ID: 15622686
[TBL] [Abstract][Full Text] [Related]
7. Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
Thorn JC; Turner EL; Hounsome L; Walsh E; Down L; Verne J; Donovan JL; Neal DE; Hamdy FC; Martin RM; Noble SM;
BMJ Open; 2016 Apr; 6(4):e011063. PubMed ID: 27130167
[TBL] [Abstract][Full Text] [Related]
8. Sarcoma epidemiology and cancer-related hospitalisation in Western Australia from 1982 to 2016: a descriptive study using linked administrative data.
Wright CM; Halkett G; Carey Smith R; Moorin R
BMC Cancer; 2020 Jul; 20(1):625. PubMed ID: 32631311
[TBL] [Abstract][Full Text] [Related]
9. Cancer outcomes in low-income elders: is there an advantage to being on Medicaid?
Koroukian SM; Bakaki PM; Owusu C; Earle CC; Cooper GS
Medicare Medicaid Res Rev; 2012; 2(2):. PubMed ID: 24800139
[TBL] [Abstract][Full Text] [Related]
10. Annual Medical Expenditure and Productivity Loss Among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States.
Zheng Z; Yabroff KR; Guy GP; Han X; Li C; Banegas MP; Ekwueme DU; Jemal A
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26705361
[TBL] [Abstract][Full Text] [Related]
11. Variations in cancer survival and patterns of care across Europe: roles of wealth and health-care organization.
Gatta G; Trama A; Capocaccia R
J Natl Cancer Inst Monogr; 2013; 2013(46):79-87. PubMed ID: 23962511
[TBL] [Abstract][Full Text] [Related]
12. Out-of-pocket medical expenses compared across five years for patients with one of five common cancers in Australia.
Rodriguez-Acevedo AJ; Chan RJ; Olsen CM; Pandeya N; Whiteman DC; Gordon LG
BMC Cancer; 2021 Sep; 21(1):1055. PubMed ID: 34563142
[TBL] [Abstract][Full Text] [Related]
13. Cost of care for elderly cancer patients in the United States.
Yabroff KR; Lamont EB; Mariotto A; Warren JL; Topor M; Meekins A; Brown ML
J Natl Cancer Inst; 2008 May; 100(9):630-41. PubMed ID: 18445825
[TBL] [Abstract][Full Text] [Related]
14. Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective.
Sagar B; Lin YS; Castel LD
J Med Econ; 2017 Oct; 20(10):1018-1023. PubMed ID: 28581874
[TBL] [Abstract][Full Text] [Related]
15. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation.
Robertson C; Arcot Ragupathy SK; Boachie C; Dixon JM; Fraser C; Hernández R; Heys S; Jack W; Kerr GR; Lawrence G; MacLennan G; Maxwell A; McGregor J; Mowatt G; Pinder S; Ternent L; Thomas RE; Vale L; Wilson R; Zhu S; Gilbert FJ
Health Technol Assess; 2011 Sep; 15(34):v-vi, 1-322. PubMed ID: 21951942
[TBL] [Abstract][Full Text] [Related]
16. Optimal post-treatment surveillance in cancer survivors: is more really better?
Shah M; Denlinger CS
Oncology (Williston Park); 2015 Apr; 29(4):230-40. PubMed ID: 25952485
[TBL] [Abstract][Full Text] [Related]
17. Estimating Costs of Care Attributable to Cancer: Does the Choice of Comparison Group Matter?
Chen AB; Li L; Cronin AM; Brooks GA; Kavanagh BD; Schrag D
Health Serv Res; 2018 Aug; 53 Suppl 1(Suppl Suppl 1):3227-3244. PubMed ID: 28858372
[TBL] [Abstract][Full Text] [Related]
18. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
[TBL] [Abstract][Full Text] [Related]
19. Access denied: The relationship between patient insurance status and access to high-volume hospitals.
Nabi J; Tully KH; Cole AP; Marchese M; Cone EB; Melnitchouk N; Kibel AS; Trinh QD
Cancer; 2021 Feb; 127(4):577-585. PubMed ID: 33084023
[TBL] [Abstract][Full Text] [Related]
20. Relationship Between Quality of Comorbid Condition Care and Costs for Cancer Survivors.
Frick KD; Snyder CF; Herbert RJ; Blackford AL; Neville BA; Wolff AC; Carducci MA; Earle CC
J Oncol Pract; 2016 Jun; 12(6):e734-45. PubMed ID: 27165487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
